Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)
Shots:
- The approval is based on study assessing Asparlas (2500 U/m2- IV- q3w) in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL
- The study resulted in achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL
- Asparlas (calaspargase pegol-mknl- IV) is an asparagine specific enzyme approved as a combination therapy for patients with ALL aged 1 month to 21 yr
Ref: The US FDA | Image: WSJ
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com